Leading Justice is a full-service marketing company working with law firms on a cash buy basis to sign up fully-qualified, fraud-free Zofran cases. Here at Leading Justice, we can customize your firm’s Zofran advertising needs and help you sign up cases via internal cash buys. Our clients simply pay an agency fee to cover the cost of Zofran advertising, plus a fee for each case we sign, and any data we generate for your firm belongs to you. In addition, we cross-qualify all of our contacts, so any data we generate that doesn’t qualify for the target campaign is reviewed to determine whether it is eligible for another type of claim. By using innovative approaches to target contacts specifically related to Zofran and birth defects like oral clefts and heart malformations, Leading Justice will increase your firm’s Zofran case load. If you are interested in helping victims of alleged Zofran birth defects, our extensive consumer reach and direct advertising strategies give you the competitive edge and confidence you need to allocate your full budget, and rest easy knowing your money is being used in the best way possible.
Each law firm we work with at Leading Justice plays an important role in how we categorize claims as qualified or not. While our experience working with plaintiff law firms allows us to recognize a great case when we see one, we will customize our Zofran case intake specifications to the exact criteria you are seeking. So, if your firm has certain Zofran qualifying case criteria you would like us to use, we can train our intake specialists to apply the criteria to each phone call and email they receive. By eliminating the middle man, Leading Justice offers clients an opportunity for internal cash buys of Zofran data with no chance of fraud.
Zofran Birth Defect Litigation
Zofran is a popular anti-nausea medication manufactured by GlaxoSmithKline and commonly prescribed to treat nausea and vomiting in patients undergoing cancer treatments like chemotherapy or radiation. However, Zofran is also often prescribed off-label to pregnant women as a treatment for a severe form of morning sickness known as hyperemesis gravidarum, a condition characterized by unrelenting pregnancy-related nausea, vomiting and dehydration that can result in malnutrition and other serious complications. According to recent reports, Zofran use in pregnancy may be linked to the following outcomes: at least two fetal deaths, fetal growth restriction in six infants, multiple reports of kidney defects, musculoskeletal abnormalities, and heart problems like atrial septal defects.
Despite the fact that Zofran has been on the market in the United States for more than 20 years, consumers and medical professionals have remained largely unaware of the potential link between Zofran use in pregnancy and devastating birth defects in babies. According to studies published in the past few years, babies exposed to Zofran in pregnancy may have double the risk of being born with a heart defect, and a 30% increased risk of developing birth defects in general. Unfortunately, because nausea and vomiting symptoms of morning sickness are estimated to affect about 70% to 85% of pregnant women during early pregnancy, many expectant mothers may take the anti-nausea medication Zofran, unaware of the risk of birth defects associated with the controversial drug.